With press reports elsewhere announcing that BioNTech AG, the Mainz, Germany-based biotech, was hiring banks to pursue an $800m IPO, for a post-money valuation approaching $4bn, the company has instead opted to raise additional venture financing through an upsized series B round of $325m. The company says the funds will be used to support the continued development of its therapeutics pipeline and manufacturing infrastructure as it strives to become of fully integrated biopharmaceutical company.
“We have always communicated that we will look at all financing options and we will continue this evaluation moving forward....





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
